Ajanta Pharma Ltd. specializes in Pharmaceuticals within the Healthcare sector.
Ajanta Pharma Ltd., with Security Code 532331, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Date Begin | Date End | Net Sales | Net Profit | Total Income | Diluted EPS for continuing operation | Other Expenses | Other Income | Depreciation and amortisation expense | Profit (+)/ Loss (-) from Ordinary Activities before Tax |
|---|---|---|---|---|---|---|---|---|---|
| 2024-01-01 | 2024-03-31 | 10,540.80 | 2,027.20 | 10,895.80 | 16.09 | -2,778.70 | 355.00 | -342.50 | 2,780.40 |
| 2024-01-01 | 2024-03-31 | 9,260.70 | 1,626.90 | 9,597.50 | 12.91 | -2,430.80 | 336.80 | -334.70 | 2,259.40 |
| 2023-10-01 | 2023-12-31 | 10,852.90 | 2,201.50 | 10,990.20 | 17.47 | -2,340.10 | 137.30 | -334.10 | 3,051.40 |
| 2023-10-01 | 2023-12-31 | 11,051.50 | 2,100.30 | 11,187.40 | 16.67 | -2,655.60 | 135.90 | -342.60 | 2,909.10 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 18% |
| 3 Years: | 13% |
| TTM: | 16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 15% |
| 3 Years: | 6% |
| TTM: | 46% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 29% |
| 3 Years: | 17% |
| 1 Year: | 53% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 15% |
| 3 Years: | 13% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 16% |
| 3 Years: | 7% |
| TTM: | 36% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 29% |
| 3 Years: | 17% |
| 1 Year: | 53% |
Ajanta Pharma on Tuesday reported a 28.21 per cent rise in its consolidated net profit to Rs 194.02 crore for the second quarter ended September 30, 2023, mainly on account of higher revenue from the domestic market.
Ajanta Pharma on Monday launched the generic version of blockbuster cancer drug Revlimid (lenalidomide) in India at a price that is 80 per cent lower than the innovator brand.
Ajanta Pharma on Thursday said it has received the final approval from the US health regulator to market its generic version of blood cancer drug imatinib mesylate in the American market.
